Journal
REGENERATIVE MEDICINE
Volume 5, Issue 4, Pages 593-603Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/RME.10.50
Keywords
allogeneic; autologous; business models; induced pluripotent stem cells; research tools; therapeutic products
Categories
Ask authors/readers for more resources
Induced pluripotent stem (iPS) cells have generated excitement in the regenerative medicine industry. Products derived from iPS cells could be used in a range of drug discovery and development processes. These nontherapeutic products will continue to be launched over the next 5 years, and provide income and knowledge to drive the therapeutic use of iPS cells forward. While the commercial opportunity for iPS cell-based therapies is potentially large, the looming technical and scientific hurdles must be overcome and, thus, the launch of a therapy based on iPS cells is unlikely to occur until the 2020s. While the launch of a therapeutic is many years away, the business models for commercialization should be well understood and proven based on experience with other non-iPS cell-based therapies (both autologous and allogeneic) that will already be on the market.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available